| Literature DB >> 28151924 |
Andre F Dailey1, Anna Satcher Johnson1, Baohua Wu1.
Abstract
Since the release of the National HIV/AIDS Strategy (NHAS) (1) and the establishment of the federal Human Immunodeficiency Virus (HIV) Care Continuum Initiative (2), federal efforts have accelerated to improve and increase HIV testing, care, and treatment and to reduce HIV-related disparities in the United States. National HIV Surveillance System (NHSS)* data are used to monitor progress toward reaching NHAS goals,† and recent data indicate that blacks have lower levels of care and viral suppression than do persons of other racial and ethnic groups (3). Among persons with HIV infection diagnosed through 2012 who were alive at year-end 2013, 68.1% of blacks received any HIV medical care compared with 74.4% of whites (3). CDC used NHSS data to describe HIV care outcomes among blacks who received a diagnosis of HIV. Among blacks with HIV infection diagnosed in 2014, 21.9% had infection classified as HIV stage 3 (acquired immunodeficiency syndrome [AIDS]) at the time of diagnosis compared with 22.5% of whites; 71.6% of blacks were linked to care within 1 month after diagnosis compared with 79.0% of whites. Among blacks with HIV infection diagnosed through 2012 who were alive on December 31, 2013, 53.5% were receiving continuous HIV medical care compared with 58.2% of whites; 48.5% of blacks achieved viral suppression compared with 62.0% of whites. Intensified efforts and implementation of effective interventions and public health strategies that increase engagement in care and viral suppression among blacks (1,4) are needed to achieve NHAS goals.Entities:
Mesh:
Year: 2017 PMID: 28151924 PMCID: PMC5657833 DOI: 10.15585/mmwr.mm6604a2
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586
Number and percentage of HIV infection diagnoses among blacks aged ≥13 years who were stage 3 (AIDS) at the time of diagnosis — National HIV Surveillance System, 33 jurisdictions,* United States, 2014
| Characteristic | No. HIV diagnoses | Stage 3 (AIDS) at diagnosis† no. (%) |
|---|---|---|
|
| ||
| Male | 9,121 | 1,908 (20.9) |
| Female | 3,148 | 780 (24.8) |
|
| ||
| 13–24 | 3,539 | 362 (10.2) |
| 25–34 | 3,832 | 700 (18.3) |
| 35–44 | 2,106 | 630 (29.9) |
| 45–54 | 1,642 | 557 (33.9) |
| ≥55 | 1,150 | 439 (38.2) |
|
| ||
| Male-to-male sexual contact | 7,393 | 1,374 (18.6) |
| Injection drug use | ||
| Male | 378 | 123 (32.5) |
| Female | 276 | 74 (26.9) |
| Male-to-male sexual contact and injection drug use | 187 | 37 (19.6) |
|
| ||
| Male | 1,144 | 369 (32.2) |
| Female | 2,859 | 700 (24.5) |
|
| ||
| Male | 19 | 6 (31.6) |
| Female | 14 | 6 (41.2) |
|
|
|
|
Abbreviations: AIDS = acquired immunodeficiency syndrome; HIV = human immunodeficiency virus.
* The 33 jurisdictions were Alabama, Alaska, California, District of Columbia, Georgia, Hawaii, Illinois, Indiana, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, New Hampshire, New Mexico, New York, North Dakota, Oregon, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.
† Stage of disease at diagnosis of HIV infection based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
§ Data statistically adjusted to account for missing transmission categories.
¶ Heterosexual contact with a person known to have or to be at high risk for HIV infection.
** Includes persons with diagnosed infection attributed to hemophilia, blood transfusion, perinatal exposure, and risk factors not reported or not identified.
Linkage to HIV medical care within 1 month after HIV diagnosis,* among blacks aged ≥13 years, by age group and selected characteristics — National HIV Surveillance System, 33 jurisdictions, United States, 2014
| Characteristic | Age group (yrs) | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13–24 | 25–34 | 35–44 | 45–54 | ≥55 | ||||||||
| No. HIV diagnoses | No. linked§ (%) | No. HIV diagnoses | No. linked§ (%) | No. HIV diagnoses | No. linked§ (%) | No. HIV diagnoses | No. linked§ (%) | No. HIV diagnoses | No. linked§ (%) | No. HIV diagnoses | No. linked§ (%) | |
|
| ||||||||||||
| Male | 3,044 | 1,945 (63.9) | 3,009 | 2,111 (70.2) | 1,338 | 999 (74.7) | 1,036 | 779 (75.2) | 694 | 548 (79.0) |
|
|
| Female | 495 | 353 (71.3) | 823 | 624 (75.8) | 768 | 584 (76.0) | 606 | 465 (76.7) | 456 | 372 (81.6) |
|
|
|
| ||||||||||||
| Male-to-male sexual contact | 2,847 | 1,821 (64.0) | 2,650 | 1,873 (70.7) | 954 | 714 (74.8) | 638 | 483 (75.7) | 303 | 234 (77.2) |
|
|
|
| ||||||||||||
| Male | 30 | 21 (70.0) | 69 | 51 (73.9) | 67 | 53 (79.1) | 93 | 66 (71.0) | 119 | 88 (73.9) |
|
|
| Female | 31 | 22 (71.0) | 57 | 38 (66.7) | 62 | 45 (72.6) | 71 | 52 (73.2) | 55 | 45 (81.8) |
|
|
| Male-to-male sexual contact and injection drug use | 51 | 28 (54.9) | 62 | 43 (69.4) | 33 | 22 (66.7) | 22 | 16 (72.7) | 19 | 16 (84.2) |
|
|
|
| ||||||||||||
| Male | 106 | 67 (63.2) | 227 | 143 (63.0) | 282 | 209 (74.1) | 281 | 213 (75.8) | 249 | 208 (83.5) |
|
|
| Female | 455 | 323 (71.0) | 764 | 584 (76.4) | 705 | 539 (76.5) | 534 | 412 (77.2) | 400 | 326 (81.5) |
|
|
|
| ||||||||||||
| Male | 9 | 8 (88.9) | 2 | 1 (50.0) | 2 | 1 (50.0) | 2 | 1 (50.0) | 4 | 3 (75.0) |
|
|
| Female | 10 | 7 (70.0) | 2 | 2 (100.0) | 0 | 0 (0.0) | 0 | 0 (0.0) | 1 | 1 (100.0) |
|
|
| Total | 3,539 | 2,298 (64.9) | 3,832 | 2,735 (71.4) | 2,106 | 1,583 (75.2) | 1,642 | 1,244 (75.8) | 1,150 | 920 (80.0) |
|
|
Abbreviation: HIV = human immunodeficiency virus.
* Data include persons with a diagnosis of HIV infection, regardless of stage of disease at diagnosis.
† The 33 jurisdictions were Alabama, Alaska, California, District of Columbia, Georgia, Hawaii, Illinois, Indiana, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, New Hampshire, New Mexico, New York, North Dakota, Oregon, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.
§ One or more CD4 or viral load tests performed within 1 month after HIV diagnosis during 2014.
¶ Data statistically adjusted to account for missing transmission categories.
** Heterosexual contact with a person known to have or to be at high risk for HIV infection.
†† Includes persons with diagnosed infection attributed to hemophilia, blood transfusion, perinatal exposure, and risk factors not reported or not identified.
Retention in HIV medical care and viral suppression among blacks aged ≥13 years with HIV infection diagnosed by December 31, 2012,* who were alive on December 31, 2013, by age group and selected characteristics — National HIV Surveillance System, 33 jurisdictions, United States, 2014
| Characteristic | Total no. | Retained in care in 2013 | Viral suppression¶ |
|---|---|---|---|
| No. (%) | No. (%) | ||
|
| |||
|
| |||
| Male |
| 89,475 (52.4) | 81,816 (47.9) |
| Female |
| 48,149 (55.6) | 43,095 (49.8) |
|
| |||
| Male-to-male sexual contact |
| 55,110 (53.2) | 50,927 (49.1) |
|
| |||
| Male |
| 13,187 (47.9) | 11,914 (43.3) |
| Female |
| 10,315 (54.8) | 8,931 (47.5) |
| Male-to-male sexual contact and injection drug use |
| 6,697 (57.3) | 5,779 (49.4) |
|
| |||
| Male |
| 13,333 (51.9) | 12,359 (48.1) |
| Female |
| 36,408 (55.7) | 33,199 (50.8) |
| Other¶¶ |
| 2,576 (56.7) | 1,803 (39.7) |
|
|
|
|
|
|
| |||
|
| |||
| Male-to-male sexual contact |
| 5,059 (50.6) | 4,102 (41.0) |
|
| |||
| Male |
| 51 (40.2) | 42 (33.1) |
| Female |
| 102 (46.6) | 65 (29.7) |
| Male-to-male sexual contact and injection drug use |
| 120 (48.8) | 96 (39.0) |
|
| |||
| Male |
| 149 (39.4) | 118 (31.2) |
| Female |
| 1,319 (53.7) | 953 (38.8) |
| Other¶¶ |
| 1,884 (58.5) | 1,238 (38.4) |
|
|
|
|
|
|
| |||
|
| |||
| Male-to-male sexual contact |
| 12,638 (50.5) | 11,110 (44.4) |
|
| |||
| Male |
| 379 (38.1) | 326 (32.7) |
| Female |
| 637 (46.1) | 506 (36.6) |
| Male-to-male sexual contact and injection drug use |
| 605 (51.4) | 493 (41.9) |
|
| |||
| Male |
| 1,006 (43.0) | 895 (38.3) |
| Female |
| 5,907 (50.3) | 4,964 (42.2) |
| Other¶¶ |
| 299 (50.9) | 218 (37.1) |
|
|
|
|
|
|
| |||
|
| |||
| Male-to-male sexual contact |
| 12,680 (52.9) | 11,909 (49.6) |
|
| |||
| Male |
| 1,441 (45.0) | 1,311 (40.9) |
| Female |
| 2,016 (51.2) | 1,679 (42.7) |
| Male-to-male sexual contact and injection drug use |
| 1,220 (54.8) | 1,028 (46.2) |
|
| |||
| Male |
| 2,860 (49.0) | 2,637 (45.2) |
| Female |
| 10,482 (52.4) | 9,549 (47.7) |
| Other¶¶ |
| 64 (48.5) | 50 (37.9) |
|
|
|
|
|
|
| |||
|
| |||
| Male-to-male sexual contact |
| 16,801 (55.7) | 15,967 (52.9) |
|
| |||
| Male |
| 5,098 (50.1) | 4,477 (44.0) |
| Female |
| 4,370 (57.2) | 3,720 (48.7) |
| Male-to-male sexual contact and injection drug use |
| 3,003 (60.6) | 2,584 (52.1) |
|
| |||
| Male |
| 5,361 (54.6) | 4,997 (50.9) |
| Female |
| 11,535 (58.7) | 10,802 (55.0) |
| Other¶¶ |
| 157 (54.7) | 139 (48.4) |
|
|
|
|
|
|
| |||
|
| |||
| Male-to-male sexual contact |
| 7,933 (54.8) | 7,838 (54.1) |
|
| |||
| Male |
| 6,219 (47.8) | 5,758 (44.3) |
| Female |
| 3,190 (56.7) | 2,961 (52.6) |
| Male-to-male sexual contact and injection drug use |
| 1,749 (56.7) | 1,577 (51.1) |
|
| |||
| Male |
| 3,956 (53.9) | 3,713 (50.6) |
| Female |
| 7,164 (62.2) | 6,931 (60.2) |
| Other¶¶ |
| 171 (53.8) | 159 (50.0) |
|
|
|
|
|
Abbreviation: HIV = human immunodeficiency virus.
* Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. Data are based on address of residence as of December 31, 2013 (i.e., most recent known address).
† The 33 jurisdictions were Alabama, Alaska, California, District of Columbia, Georgia, Hawaii, Illinois, Indiana, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, New Hampshire, New Mexico, New York, North Dakota, Oregon, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.
§ Defined as having two or more CD4 or viral load tests performed ≥3 months apart during 2013, among persons diagnosed through December 31, 2012, and alive on December 31, 2013.
¶ Defined as having a viral load result of ≤200 copies/mL at the most recent viral load test during 2013. The cutoff value of ≤200 copies/mL was based on the U.S. Department of Health and Human Services recommended definition of virologic failure.
** Age at year-end 2013.
†† Data statistically adjusted to account for missing transmission categories.
§§ Heterosexual contact with a person known to have or to be at high risk for HIV infection.
¶¶ Includes persons with diagnosed infection attributed to hemophilia, blood transfusion, perinatal exposure, and risk factors not reported or not identified.